The products will be distributed under BioGaia’s own brand through the retail pharmacy channel in the region.
BioGaia chief executive officer Peter Rothschild said, "We are pleased with the new agreement as it means that our products will be available in our traditional distribution channel in a market with good potential; South Korea has 50 million inhabitants and is ranked as the country with the 15th strongest purchasing power in the world."
ProTectis baby drops and ProTectis tablets comprise patented probiotic strain Lactobacillus reuteri Protectis.
BioGaia Gastrus is currently being developed for patients with Helicobacter pylori infection.